Previous studies have established that early treatment of HIV dramatically reduces the odds of spreading the infection to a sexual partner. The START trial provides evidence that early therapy benefits a patient's own health.
Interest in preexposure prophylaxis is high among a diverse population of men who have sex with men who are at risk for HIV infection.
A large increase in HIV and HCV infections in Indiana among injection drug users has prompted the CDC to issue a nationwide public health alert. Here's what you can do.
Rates of postoperative mortality among HIV-infected individuals who are receiving ART are low and influenced as much by hypoalbuminemia and age as by CD4 cell status, according to a new study.
Screening for tobacco use and strategies for quitting are important considerations for patients with HIV, since infected adults are more likely to smoke -- and less likely to quit -- than those who are uninfected.
A new study shows that it is safe to fall back on an NRTI-only regimen in special circumstances in patients with adequately suppressed HIV replication.
HIV infection increases the risk of acute myocardial infarction in veterans without major cardiovascular disease risk factors. The presence of major CVD risk factors significantly increases this risk.
HIV-infected men appear to be using testosterone replacement without adequate baseline evaluation and establishment of recommended indications.
Here's why it is important for everyone infected with HIV to get an influenza vaccination.
“Enough time” is one of the necessary components of what it takes to be a “good” doctor. Here’s how this doctor defines “enough.”
Statins effectively lower levels of various pro-inflammatory markers of immune activation. So can statin therapy prevent CVD events in HIV-infected persons?
Details here about a quick reference guide for HIV primary care clinicians caring for HIV in older adults.
The FDA proposes to ease its lifetime ban on blood donations by men who have sex with men (MSM), but proposes to block donations by MSM within the last year. Here’s the rationale.
This AIDS specialist offers his rank-order list of the top 10 HIV clinical trials that really made a difference. The trials differ substantially in design, size, and focus, but they all were “game changers.”
If full restoration of immunologic and clinical health is the goal of antiretroviral therapy, the best chance we have is to start ART within 12 months of infection.